Blab Business
UnitedHealths Optum Rx and Emisar Reach Tentative Settlement with FTC Over Insulin Pricing Allegations
UnitedHealth Group’s pharmacy‑benefit arm Optum Rx and its group‑purchasing organization Emisar have entered a tentative settlement with the Federal Trade Commission (FTC) over a lawsuit that accuses the three largest pharmacy benefit managers (PBMs) of inflating insulin prices.
The FTC has paused the administrative proceeding against Optum Rx and Emisar while it reviews a proposed consent agreement that, if approved by FTC leadership, would resolve the agency’s claims in their entirety. The order, released Friday, notes that the consent agreement has been approved by directors of the FTC’s bureaus of competition and consumer protection, but the specific terms remain undisclosed.
The complaint, filed in 2024, alleges that CVS Health’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx used uncompetitive practices to raise the cost of insulin. The agency argues that the PBMs steer patients toward higher‑priced drugs to secure larger rebates from manufacturers, thereby driving up the list price that patients ultimately pay. Together, the three companies control roughly 80 percent of U.S. prescription volume, giving them substantial influence over drug pricing and reimbursement.
Express Scripts settled its portion of the case in early February, agreeing to decouple its compensation from the savings it negotiates with pharmaceutical companies and to stop favoring higher‑priced medications, among other measures. CVS Health reached a proposed settlement in late March, though the deal has not yet been finalized. Optum Rx is now the last of the three PBMs to move toward an agreement.
According to the FTC order, the consent agreement would “resolve the claims against the Optum Respondents in their entirety.” The agency has not released the specific commitments that Optum would make. Optum Rx has not yet responded to a request for comment, and an FTC spokesperson said the agency had no comment.
The FTC’s complaint focuses on insulin, a medication that has seen a dramatic price increase over the past decade. The investigation has highlighted how PBM rebate structures can create incentives for higher list prices, which in turn increase the cost burden on patients and health plans.
UnitedHealth Group, the parent company of Optum, is the largest health insurer in the United States, covering more than 50 million people. Optum’s pharmacy‑benefit arm, Optum Rx, is a major player in the PBM market, and its group‑purchasing organization Emisar also falls under the same regulatory scrutiny. The tentative settlement could signal a shift in the industry’s approach to drug pricing and rebate arrangements.
The FTC’s order does not indicate whether the settlement will be binding or whether it will require additional oversight. The agency’s next steps will involve reviewing the proposed agreement and determining whether it satisfies the agency’s antitrust and consumer‑protection objectives. If approved, the settlement would end the FTC’s administrative proceeding against Optum Rx and Emisar, allowing the company to resume normal operations without the threat of further enforcement action.
The outcome of the Optum settlement may influence future regulatory actions against other PBMs and could set a precedent for how the industry addresses rebate and pricing practices. Investors and industry observers will watch for the FTC’s final decision, which could come in the coming weeks. The settlement also raises questions about the broader impact on insulin pricing and patient access, which remain key concerns for policymakers and consumer advocates.
In summary, UnitedHealth’s Optum Rx and Emisar have entered a tentative settlement with the FTC over allegations of inflating insulin prices. The FTC has paused the case pending review of a consent agreement approved by agency directors, though the terms are undisclosed. The settlement follows earlier agreements by Express Scripts and a proposed deal by CVS Caremark. The FTC will decide whether to accept the agreement, potentially ending enforcement action against Optum and shaping future PBM regulation.
The FTC has paused the administrative proceeding against Optum Rx and Emisar while it reviews a proposed consent agreement that, if approved by FTC leadership, would resolve the agency’s claims in their entirety. The order, released Friday, notes that the consent agreement has been approved by directors of the FTC’s bureaus of competition and consumer protection, but the specific terms remain undisclosed.
The complaint, filed in 2024, alleges that CVS Health’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx used uncompetitive practices to raise the cost of insulin. The agency argues that the PBMs steer patients toward higher‑priced drugs to secure larger rebates from manufacturers, thereby driving up the list price that patients ultimately pay. Together, the three companies control roughly 80 percent of U.S. prescription volume, giving them substantial influence over drug pricing and reimbursement.
Express Scripts settled its portion of the case in early February, agreeing to decouple its compensation from the savings it negotiates with pharmaceutical companies and to stop favoring higher‑priced medications, among other measures. CVS Health reached a proposed settlement in late March, though the deal has not yet been finalized. Optum Rx is now the last of the three PBMs to move toward an agreement.
According to the FTC order, the consent agreement would “resolve the claims against the Optum Respondents in their entirety.” The agency has not released the specific commitments that Optum would make. Optum Rx has not yet responded to a request for comment, and an FTC spokesperson said the agency had no comment.
The FTC’s complaint focuses on insulin, a medication that has seen a dramatic price increase over the past decade. The investigation has highlighted how PBM rebate structures can create incentives for higher list prices, which in turn increase the cost burden on patients and health plans.
UnitedHealth Group, the parent company of Optum, is the largest health insurer in the United States, covering more than 50 million people. Optum’s pharmacy‑benefit arm, Optum Rx, is a major player in the PBM market, and its group‑purchasing organization Emisar also falls under the same regulatory scrutiny. The tentative settlement could signal a shift in the industry’s approach to drug pricing and rebate arrangements.
The FTC’s order does not indicate whether the settlement will be binding or whether it will require additional oversight. The agency’s next steps will involve reviewing the proposed agreement and determining whether it satisfies the agency’s antitrust and consumer‑protection objectives. If approved, the settlement would end the FTC’s administrative proceeding against Optum Rx and Emisar, allowing the company to resume normal operations without the threat of further enforcement action.
The outcome of the Optum settlement may influence future regulatory actions against other PBMs and could set a precedent for how the industry addresses rebate and pricing practices. Investors and industry observers will watch for the FTC’s final decision, which could come in the coming weeks. The settlement also raises questions about the broader impact on insulin pricing and patient access, which remain key concerns for policymakers and consumer advocates.
In summary, UnitedHealth’s Optum Rx and Emisar have entered a tentative settlement with the FTC over allegations of inflating insulin prices. The FTC has paused the case pending review of a consent agreement approved by agency directors, though the terms are undisclosed. The settlement follows earlier agreements by Express Scripts and a proposed deal by CVS Caremark. The FTC will decide whether to accept the agreement, potentially ending enforcement action against Optum and shaping future PBM regulation.
